Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

Jefferies analyst Keith Devas initiated coverage with a Buy rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target ...

On October 23, 2024, Johnson & Johnson (NYSE:JNJ), the world's largest and most diverse healthcare firm, filed its 10-Q ...

On Tuesday, Kenvue Inc (KVUE) stock saw a modest uptick, ending the day at $22.93 which represents a slight increase of $0.01 or 0.04% from the prior close of $22.92. The stock opened at $22.55 and ...

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Financial writer analyzes activist hedge fund CEO's call for Kenvue to revamp skincare, health, and beauty segments for ...

An exclusive Q&A with David Lickstein, Global Head of Packaging Innovation, Sustainability, and Experience, at Kenvue ...

Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...